Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT02119650

Public ClinicalTrials.gov record NCT02119650. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study was to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent.

Study identification

NCT ID
NCT02119650
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Incyte Corporation
Industry
Enrollment
76 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 10, 2014
Primary completion
Feb 10, 2016
Completion
Jun 20, 2016
Last update posted
Feb 12, 2018

2014 – 2016

United States locations

U.S. sites
30
U.S. states
21
U.S. cities
30
Facility City State ZIP Site status
Not listed Phoenix Arizona
Not listed Fayetteville Arkansas
Not listed Fresno California
Not listed La Jolla California
Not listed San Diego California
Not listed San Francisco California
Not listed Lone Tree Colorado
Not listed Norwich Connecticut
Not listed Southington Connecticut
Not listed Augusta Georgia
Not listed Joliet Illinois
Not listed Indianapolis Indiana
Not listed Lafayette Indiana
Not listed Kansas City Kansas
Not listed Detroit Michigan
Not listed St Louis Missouri
Not listed Reno Nevada
Not listed Lebanon New Hampshire
Not listed Mount Kisco New York
Not listed New York New York
Not listed Winston-Salem North Carolina
Not listed Canton Ohio
Not listed Portland Oregon
Not listed Chattanooga Tennessee
Not listed Knoxville Tennessee
Not listed Memphis Tennessee
Not listed Ogden Utah
Not listed Leesburg Virginia
Not listed Kennewick Washington
Not listed Seattle Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02119650, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 12, 2018 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02119650 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →